Restless Leg Syndrome More Common in Psoriasis Patients
THURSDAY, Dec. 15, 2022 -- Restless leg syndrome (RLS) is more common in psoriasis patients and is associated with more severe psoriasis, according to a study published online Dec. 5 in the International Journal of Dermatology.
Berna Solak, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 15, 2022 Category: Pharmaceuticals Source Type: news
In a $6B deal, Cambridge biotech sells experimental psoriasis drug to Takeda
In one of the largest acquisitions of a drug this year, Takeda has agreed to buy a drug in mid-stage development for autoimmune diseases for $4 billion upfront plus $2 billion in milestone payments from Cambridge-based Nimbus Therapeutics. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 13, 2022 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news
Alcohol Consumption and Smoking in Relation to Psoriasis Alcohol Consumption and Smoking in Relation to Psoriasis
This study aimed to determine whether smoking or alcohol consumption increases the risk of psoriasis.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 5, 2022 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Man, 42, receives fatty liver diagnosis after 'severe' rash spreads to 50% of his body
Estimations put the prevalence of non-alcoholic fatty liver disease in psoriasis patients at 47 percent. (Source: Daily Express - Health)
Source: Daily Express - Health - November 30, 2022 Category: Consumer Health News Source Type: news
Isolated Nail Psoriasis Does Not Increase Risk for Metabolic Syndrome
TUESDAY, Nov. 22, 2022 -- Isolated nail psoriasis (NP) is not significantly associated with an increased risk for metabolic syndrome, according to a letter to the editor recently published in the Journal of the European Academy of Dermatology&... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 22, 2022 Category: Pharmaceuticals Source Type: news
Which medicines, taken by mouth or injected, work best to treat a skin condition called plaque psoriasis?
Tuesday, November 22, 2022 (Source: Cochrane News and Events)
Source: Cochrane News and Events - November 22, 2022 Category: Information Technology Authors: Paolo Rosati Source Type: news
New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population
SPRING HOUSE, PENNSYLVANIA, November 11, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER program (DISCOVER-1 and DISCOVER-2) evaluating TREMFYA® (guselkumab) in adult patients with active psoriatic arthritis (PsA), which showed that early skin and enthesitis responsesa,b predicted longer-term clinical response,c including disease remission, at week 52.1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor therapy approved in the U.S. for adults with moderate to severe plaque psoriasis (PsO) and adults with active PsA...
Source: Johnson and Johnson - November 11, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
New Onset/Exacerbations of Psoriasis After COVID-19 Vaccines New Onset/Exacerbations of Psoriasis After COVID-19 Vaccines
Might COVID-19 vaccination be a triggering factor for psoriasis? This paper reveals that both new-onset psoriasis and psoriasis flares have been reported following COVID-19 vaccination.American Journal of Clinical Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 11, 2022 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life
SPRING HOUSE, PENNSYLVANIA, November 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER-2 study that show early (week 8) clinical improvementsa of most measures (joint and skin disease, enthesitis and dactylitis) in adult patients with active psoriatic arthritis (PsA) treated with TREMFYA® (guselkumab) were associated with meaningful improvements in health-related quality of life (HRQoL) (measured by EQ-5D)b from year one (week 52) through year two (week 100).1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor th...
Source: Johnson and Johnson - November 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Psoriasis Not Tied to Myocardial Infarction in Patients With ESRD
TUESDAY, Nov. 1, 2022 -- Among individuals with end-stage renal disease (ESRD), psoriasis is not associated with an increased risk for myocardial infarction (MI), according to a study recently published in the American Journal of the Medical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 1, 2022 Category: Pharmaceuticals Source Type: news
What Causes Anal Itching?
Discussion
Pinworms are caused by the parasite Enterobius vermicularis. Humans are the only known reservoir and are infected by fecal-oral transmission of eggs or indirectly such as through contaminated clothing or bedding. It is commonly seen in children and can easily pass to family members, plus people can become easily reinfected. The incubation period is usually 1-2 months and eggs can survive outside humans for 2-3 weeks. Adult worms migrate at night from the anus to the perianal skin and vulvar areas causing anal or vulvar itching. The itching can cause sleep problems and scratching can cause secondary bacterial inf...
Source: PediatricEducation.org - October 31, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Biomarkers of Systemic Treatment Response in Psoriasis Biomarkers of Systemic Treatment Response in Psoriasis
This review provides a comprehensive catalog of candidate biomarkers of systemic treatment response in psoriasis.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 28, 2022 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Feature: Answers to Your Psoriasis Questions
If you've been diagnosed with psoriasis, you probably have some questions. We have answers. (Source: WebMD Health)
Source: WebMD Health - October 24, 2022 Category: Consumer Health News Source Type: news
Biologics for Psoriasis
Biologic treatments for psoriasis can help clear your skin and ease symptoms, but there are some risk factors to consider. Here’s what you need to know. (Source: WebMD Health)
Source: WebMD Health - October 24, 2022 Category: Consumer Health News Source Type: news
New TREMFYA ® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with moderately to severely active ulcerative colitis (UC) with inadequate responses to previous treatments. The data presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting show an overall clinical response rate of approximately 80 percent in patients who were randomized to TREMFYA® (guselkumab).Clinical responsea at weeks 12 or 24 of the study was ultimately achieved by 80.2 percent of patients who w...
Source: Johnson and Johnson - October 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
